A Pilot Study Evaluating a Novel Magneto-Fluidic System for Ultra-High Throughput Detection of Circulating Tumor Cells in Patients with Metastatic and Loco-regional Urothelial Bladder Cancer IUSCC-0552

H
Hristos Kaimakliotis, MD

Primary Investigator

Overview

The purpose of this study is to determine if cancer cells in blood can be reliably detected in bladder cancer patients using a new blood test known as a "liquid biopsy."

Description

The purpose of this study is to test and optimize this magneto-fluidic system we have developed to capture circulating tumor cells from samples of patients with advanced urothelial bladder cancer, and potentially applu this system to an earlier clinical stage cohort to predict advanced pathology.

Eligibility

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    bladder cancer
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria
Patients must have histologically confirmed advanced urothelial bladder cancer, specifically metastatic or muscle invasive disease
Previously untreated patients and patients with prior therapies will be allowed as long as therapy was give > or = 3 weeks prior to blood collection


Additional Information:
Participants will not be paid for their participation.

Updated on 20 Nov 2022. Study ID: 1601654610

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center